Had the privilege of representing SIDP at the #IDWeek2023 planning committee meeting over the past two days which was a blast! Amazing teamwork by each of the committees and I can’t wait for everyone to experience all of the great content planned for Boston this fall!

Isavuconazole is the only US FDA-approved antifungal for treating invasive mucormycosis 🆕️⚡️⚡️ #JOF Mariana Castanheira Antifungal Activity of Isavuconazole and Comparator Agents against Contemporaneous Mucorales Isolates from USA, Europe, and Asia-Pacific mdpi.com/2309-608X/9/2/…

Guess what? We are growing (again) and adding another position! Come join us at MD Anderson and help us take care of our immunocompromised patient population. You’ll even be included in our next portrait! (costume or sunglasses not included) Apply here: jobs.mdanderson.org/search/jobdeta…

So proud of our ⭐ brilliant ⭐ Stanford Infectious Diseases Program fellows Alex Zimmet Ralph Tayyar and Krithi Srinivasan presenting research at #SHEASpring2023! Rock stars! 🤩

Invasive mucormycosis is an uncommon infix that has been associated with high rates of mortality. Differences in pt host factors, dx presentation, and mgmt practices have made it difficult to ascertain efficacy of interventions with invasive mucormycosis. MAD-ID The Antimicrobial Stewardship Meeting®️ #MADID2023

Proud of Brian Lu (Brian Lu) our PGY2 ID resident on presenting his poster at #MADID2023 on invasive mucormycosis! Will A Marisa Holubar Stan Deresinski Jessica Ferguson @Pharm_Bean Emily Mui

“Race and ethnicity were determined by clinicians and were not self-reported” -Paper published in JAMA Genuinely curious how a clinician would make that determination 🤷🏽‍♂️

Nagel Pharmily Reunion IDWeek! (Missing Marie, Twisha, Farnaz, Will A Nikki Tran) #IDWeek2023 @MMAbxStew

Great session with 🌟panelists. Great to see two of my personal mentors on stage Marisa Holubar Payal K. Patel who have helped shape my own career! IDSA SIDP #IDWeek2023

🆕️🔥 Single centre cohort study Stanford Antimicrobial Stewardship Brian Lu David Ha &🌟s* In immunocompromised pts with Invasive Mucormycosis neither upfront nor salvage antifungal combo Rx was associated with a difference in 6 week mortality compared to monotherapy academic.oup.com/ofid/advance-a…

Combination Antifungal Therapy for Invasive Mucormycosis in Immunocompromised Hosts: A Single-Center Experience ✅ Just Accepted 🔓 Open Access 🔗 bit.ly/3OTb8OF David Ha Jessica Ferguson @Pharm_Bean Emily Mui Stan Deresinski Marisa Holubar Will A

Congrats, Alex (Alex Zimmet), David (David Ha), Emily (Emily Mui), Mary Smith, Marty (Marten Hawkins), Will (Will A), and Marisa (Marisa Holubar)! More excellent work from our awesome stewardship department headed up by Dr. Marisa Holubar!

Our Stanford Infectious Diseases Program fellows are all exceptional. Great job, Alex Zimmet! 👏🏽

Next up is Dr. Will Allegria to talk about stewardship in Immunocompromised patients. This is a complicated patient population. #SHEASpring2024 1/

Question for #TxID #IDTwitter Does your center provide different abx surg ppx recs for kidneys coming from deceased vs living donors? Ex pip tazo for deceased vs cefazolin for living. Also, any difference in duration of abx ppx (eg 48 vs <24 hrs) transplantid.net Stanford Antimicrobial Stewardship

Will A transplantid.net Stanford Antimicrobial Stewardship 👋 Will A! Not sure if our peds experience is of interest but our center recs cefazolin x 24 hr post-kidney transplant regardless of deceased or living donor. Donor or recipient cultures preceding may be taken into consideration. Looking forward to hearing other responses!

Creative combination treatment ideas for this isolate? CF patient s/p lung transplant in 2022. Will A David Ha @jfsisaacs5

Thank you Stanford Infectious Diseases Fellowship for this recognition.. Can’t wait to see all the amazing things you’ll do!